Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

Insulet (Nasdaq:PODD) announced that it successfully defended its intellectual property against EOFlow in U.S. federal court.

but more recent models have taken the form of a patch with a pump mounted directly upon it. When [Pete Schwamb]’s daughter received one of these pumps, an Omnipod, he responded to a bounty ...

Insulet Corp.’s PODD groundbreaking Omnipod 5 Automated Insulin Delivery (“AID”) system (Omnipod 5) received the FDA’s approval for use by type 2 diabetes patients (ages 18 years and above).

The CEO also expects competition in closed-loop devices for people with Type 2 diabetes to intensify, with Insulet receiving FDA clearance for its Omnipod 5 patch pump for Type 2 diabetes in August.